Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...

Using a kind of novel linker technology, the startup is developing versions of incretin and non-incretin therapies that can ...

An unusual tussle over the availability of funds for Apple Tree’s startups led the firm to seek protection from creditors ...

The agency gave the green light to a U.S. company manufacturing Augmentin XR, an antibiotic first approved more than two ...

The data and AI algorithms within companion apps can help HCPs provide a diagnosis quicker, allowing them to compare their ...

CAR-T cancer therapies now need to succeed in randomized, controlled trials to earn approvals. Elsewhere, a drug from Bristol ...

Shares of AC Immune rose by double-digits on news that the company, encouraged by new data, now intends to ask drug ...

PsiThera, formerly Psivant Therapeutics, raised just over $47 million for oral drugs targeting “diseases long-constrained by ...

A potentially $2 billion deal with a subsidiary of Shanghai-based Fosun Pharma gives Pfizer a new chance at an oral weight ...

In a step forward for bispecific antibodies, study results presented at ASH suggest a Tecvayli-based combination could have ...

The legislation, which is scheduled for a vote Thursday, would send funds directly to health savings accounts paired with ...

The deal, which includes another $200 million in potential payouts, hands the California biotech a candidate in late-stage ...